Amedeo Smart

Free Medical Literature Service


 

Amedeo

Stroke

  Free Subscription

Articles published in
Lancet Neurol
    April 2024
  1. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dysphagia after stroke: research advances in treatment interventions.
    Lancet Neurol. 2024;23:418-428.
    >> Share

  2. SEIFFGE DJ, Cancelloni V, Raber L, Paciaroni M, et al
    Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
    Lancet Neurol. 2024;23:404-417.
    >> Share

  3. SPOSATO LA, Andrade JG, Field TS
    Detection of atrial fibrillation in patients after stroke - Authors' reply.
    Lancet Neurol. 2024;23:336-337.
    >> Share

  4. SIONTIS KC, Noseworthy PA, Friedman PA
    Detection of atrial fibrillation in patients after stroke.
    Lancet Neurol. 2024;23:335-336.
    >> Share

  5. KANDEL A, Arjyal A, Karmacharya B, Gajurel B, et al
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:334.
    >> Share

  6. FEIGIN VL, Yaria J, Owolabi M
    Pragmatic solutions for the global burden of stroke - Authors' reply.
    Lancet Neurol. 2024;23:334-335.
    >> Share

  7. SCHLOGL M, Quinn TJ
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:333-334.
    >> Share


  8. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:344-381.
    >> Share

    February 2024
  9. MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al
    Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
    Lancet Neurol. 2024;23:157-167.
    >> Share

  10. GANESH A
    Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke.
    Lancet Neurol. 2024;23:125-127.
    >> Share

  11. SIMUNI T, Chahine LM, Poston K, Brumm M, et al
    A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research.
    Lancet Neurol. 2024;23:178-190.
    >> Share

  12. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    >> Share

    January 2024
  13. SHARMA M, Molina CA, Toyoda K, Bereczki D, et al
    Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Lancet Neurol. 2024;23:46-59.
    >> Share

  14. KHATRI P
    Anticoagulants to prevent recurrent non-cardioembolic stroke.
    Lancet Neurol. 2024;23:3-5.
    >> Share

  15. ANDERSON CS
    Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage.
    Lancet Neurol. 2024;23:12-13.
    >> Share

    December 2023
  16. BRIGO F
    The (hi)story of stroke.
    Lancet Neurol. 2023;22:1110.
    >> Share

  17. UCHIYAMA S
    Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.
    Lancet Neurol. 2023;22:1091-1092.
    >> Share

  18. ABBOTT A, Schott L, Gao L, Budincevic H, et al
    Carotid artery overtreatment in the USA.
    Lancet Neurol. 2023;22:1102-1103.
    >> Share

    November 2023
  19. KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al
    Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial.
    Lancet Neurol. 2023;22:991-1004.
    >> Share

  20. RUBIANO AM, Lee K
    Traumatic brain injury research: homogenising heterogeneity.
    Lancet Neurol. 2023;22:973-975.
    >> Share

  21. ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al
    Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
    Lancet Neurol. 2023;22:1061-1074.
    >> Share

    October 2023
  22. MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al
    Digital mobility measures to predict Parkinson's disease.
    Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376.
    >> Share

  23. SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al
    Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326.
    >> Share

  24. AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al
    Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315.
    >> Share

  25. KAMEL H
    Reassessing the implications of atrial fibrillation detected after stroke.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406.
    >> Share

  26. BRUSCA SB, Albert MA
    Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386.
    >> Share

  27. WATKINS DA
    Policy priorities for preventing stroke-related mortality and disability worldwide.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387.
    >> Share

  28. FEIGIN VL, Owolabi MO
    Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.
    Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277.
    >> Share

  29. MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al
    Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
    Lancet Neurol. 2023;22:946-958.
    >> Share

  30. IZZY S, Grashow R, Radmanesh F, Chen P, et al
    Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention.
    Lancet Neurol. 2023;22:959-970.
    >> Share

    September 2023
  31. HUGGER SS, Do TP, Ashina H, Goicochea MT, et al
    Migraine in older adults.
    Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206.
    >> Share

  32. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
    The assessment of dysphagia after stroke: state of the art and future directions.
    Lancet Neurol. 2023;22:858-870.
    >> Share

  33. FENG W
    Diagnosis of post-stroke dysphagia: towards better treatment.
    Lancet Neurol. 2023;22:778-779.
    >> Share

  34. OSPEL JM, Goyal M
    Prehospital triage in acute stroke: which questions to ask?
    Lancet Neurol. 2023;22:771-772.
    >> Share

  35. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
    Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
    Lancet Neurol. 2023;22:812-825.
    >> Share

  36. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
    Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
    Lancet Neurol. 2023;22:800-811.
    >> Share

    August 2023
  37. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
    The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
    Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
    >> Share

  38. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
    Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
    >> Share

  39. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
    Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
    Lancet Neurol. 2023;22:750-768.
    >> Share

  40. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
    Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
    Lancet Neurol. 2023;22:712-722.
    >> Share

  41. MAYNARD G, Kannan R, Liu J, Wang W, et al
    Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
    Lancet Neurol. 2023;22:672-684.
    >> Share

  42. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
    Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2023;22:661-671.
    >> Share

    July 2023
  43. ENGLISH C, Ramage E
    Secondary stroke prevention: more questions than answers.
    Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.
    >> Share

  44. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
    The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
    >> Share

  45. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Lancet Neurol. 2023;22:557-567.
    >> Share

  46. FRISONI GB, van der Flier W
    STRIVEing to describe small vessel disease.
    Lancet Neurol. 2023;22:548-549.
    >> Share

  47. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Lancet Neurol. 2023;22:578-590.
    >> Share

  48. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
    Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Lancet Neurol. 2023;22:568-577.
    >> Share

  49. MEISEL A
    Are CAR T cells the answer to myasthenia gravis therapy?
    Lancet Neurol. 2023;22:545-546.
    >> Share

    June 2023
  50. VAN DER MERWE J
    Stroke care quality-why recognition matters.
    Lancet Neurol. 2023;22:471.
    >> Share

  51. HAYWARD KS, Bernhardt J
    Aspiring to restore arm and hand function after stroke.
    Lancet Neurol. 2023;22:464-465.
    >> Share

    May 2023
  52. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
    Neuroimaging standards for research into small vessel disease-advances since 2013.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
    >> Share

  53. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
    Progression of cerebral amyloid angiopathy: a pathophysiological framework.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
    >> Share

  54. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Neurol. 2023;22:395-406.
    >> Share

  55. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Lancet Neurol. 2023;22:383-394.
    >> Share

  56. KASKI D, Koohi N, Haider S, Chandratheva A, et al
    The hyperacute vestibular syndrome: ear or brain?
    Lancet Neurol. 2023;22:377-378.
    >> Share

    April 2023
  57. WU S, Anderson CS
    Antiplatelets for secondary stroke prevention in China.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.
    >> Share

  58. PAN Y, Meng X, Yuan B, Johnston SC, et al
    Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
    >> Share

  59. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
    Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lancet Neurol. 2023;22:320-329.
    >> Share

  60. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
    Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
    Lancet Neurol. 2023;22:312-319.
    >> Share

  61. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
    The International Stroke Recovery and Rehabilitation Alliance.
    Lancet Neurol. 2023;22:295-296.
    >> Share

  62. MAZIGHI M
    The quest for optimal blood pressure management after stroke.
    Lancet Neurol. 2023;22:285-286.
    >> Share

  63. FEIGIN VL, Brainin M, Martins SCO
    The polypill from a public-health perspective.
    Lancet Neurol. 2023;22:294-295.
    >> Share

    March 2023
  64. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
    Thrombolysis for acute ischaemic stroke: current status and future perspectives.
    Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
    >> Share

  65. REIFF T, Eckstein HH, Mansmann U, Hacke W, et al
    Treatment of asymptomatic carotid stenosis in SPACE-2 - Authors' reply.
    Lancet Neurol. 2023;22:198-199.
    >> Share

  66. SPENCE JD
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197-198.
    >> Share

  67. GOEL A, Soteriou I, Normando E
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197.
    >> Share

  68. THORNTON CA, Moxley RT 3rd, Eichinger K, Heatwole C, et al
    Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
    Lancet Neurol. 2023;22:218-228.
    >> Share

  69. LIPTON RB, Croop R, Stock DA, Madonia J, et al
    Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
    Lancet Neurol. 2023;22:209-217.
    >> Share

    February 2023
  70. ALEMSEGED F, Nguyen TN, Coutts SB, Cordonnier C, et al
    Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice.
    Lancet Neurol. 2023 Feb 10:S1474-4422(22)00483.
    >> Share

  71. MONICHE F, Cabezas-Rodriguez JA, Valverde R, Escudero-Martinez I, et al
    Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Lancet Neurol. 2023;22:137-146.
    >> Share

  72. SAVITZ SI
    Intra-arterial bone marrow mononuclear cells for stroke.
    Lancet Neurol. 2023;22:105-106.
    >> Share

    January 2023
  73. GOYAL M, Singh N, Ospel J
    Clinical trials in stroke in 2022: new answers and questions.
    Lancet Neurol. 2023;22:9-10.
    >> Share

  74. JENSEN M, Suling A, Metzner A, Schnabel RB, et al
    Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial.
    Lancet Neurol. 2023;22:45-54.
    >> Share

  75. DROUIN E, Pasquini M, Hautecoeur P
    The advent of stroke units.
    Lancet Neurol. 2023;22:31.
    >> Share

  76. CALVERT P, Gupta D, Lip GYH
    Early atrial fibrillation rhythm control after stroke.
    Lancet Neurol. 2023;22:3-4.
    >> Share

  77. PENSATO U, Romoli M, Lazzarin SM, Marcheselli S, et al
    The shortage of thrombolytics for stroke: a call for action.
    Lancet Neurol. 2023;22:28.
    >> Share

    December 2022
  78. ROALDSEN MB, Eltoft A, Wilsgaard T, Christensen H, et al
    Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00484.
    >> Share

  79. MUIR KW
    Treatment of wake-up stroke: stick or TWIST?
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00515.
    >> Share

  80. THE LANCET NEUROLOGY
    Tackling the burden of stroke with primordial prevention.
    Lancet Neurol. 2022;21:1061.
    >> Share

  81. SOILEAU MJ, Aldred J, Budur K, Fisseha N, et al
    Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:1099-1109.
    >> Share

    November 2022
  82. KUHLMANN T, Moccia M, Coetzee T, Cohen JA, et al
    Multiple sclerosis progression: time for a new mechanism-driven framework.
    Lancet Neurol. 2022 Nov 18:S1474-4422(22)00289.
    >> Share

  83. CHURILOV L, Bivard A, Parsons MW
    Tenecteplase versus alteplase for early treatment of ischaemic stroke - Authors' reply.
    Lancet Neurol. 2022;21:959.
    >> Share

  84. HUDAIB AR
    Tenecteplase versus alteplase for early treatment of ischaemic stroke.
    Lancet Neurol. 2022;21:959.
    >> Share

    October 2022
  85. HOU C, Lan J, Lin Y, Song H, et al
    Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00335.
    >> Share

  86. GANESH A, Smith EE, Hill MD
    Remote ischaemic conditioning for stroke prevention.
    Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00438.
    >> Share

  87. HOBEANU C, Lavallee PC, Charles H, Labreuche J, et al
    Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.
    Lancet Neurol. 2022;21:889-898.
    >> Share

  88. REIFF T, Eckstein HH, Mansmann U, Jansen O, et al
    Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial.
    Lancet Neurol. 2022;21:877-888.
    >> Share

  89. BURTON A
    Valeria Caso: because women have strokes too.
    Lancet Neurol. 2022;21:873.
    >> Share

  90. CHRISTENSEN H
    Long-term disability after transient ischaemic attack or minor stroke.
    Lancet Neurol. 2022;21:859-860.
    >> Share

    September 2022
  91. PETER-DEREX L, Philippeau F, Garnier P, Andre-Obadia N, et al
    Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Neurol. 2022;21:781-791.
    >> Share

  92. SYKES L, Akpalu A, Gordon C, Cullen L, et al
    Developing stroke care services in west Africa.
    Lancet Neurol. 2022;21:778-779.
    >> Share

  93. VAN DEN BERG SA, Uniken Venema SM, Reinink H, Hofmeijer J, et al
    Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00333.
    >> Share

  94. SANDSET EC, Walter S, Song L
    The challenges of large-scale prehospital stroke trials.
    Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00356.
    >> Share

    August 2022
  95. BRAININ M, Grisold W, Hankey GJ, Norrving B, et al
    Time to revise primary prevention guidelines for stroke and cardiovascular disease.
    Lancet Neurol. 2022;21:686-687.
    >> Share

    June 2022
  96. BAAK LM, Wagenaar N, van der Aa NE, Groenendaal F, et al
    Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
    Lancet Neurol. 2022;21:528-536.
    >> Share

  97. GONZALEZ F, Ferriero DM
    Stem cells for perinatal stroke.
    Lancet Neurol. 2022;21:497-499.
    >> Share

  98. THE LANCET NEUROLOGY
    No area of stroke research should be left behind.
    Lancet Neurol. 2022;21:495.
    >> Share

    May 2022
  99. ROTHWELL PM
    20 years of improvement in stroke care: the rewards from finally funding more research.
    Lancet Neurol. 2022;21:402-404.
    >> Share

    April 2022
  100. BIVARD A, Zhao H, Churilov L, Campbell BCV, et al
    Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00171.
    >> Share

  101. KVISTAD CE, Naess H, Helleberg BH, Idicula T, et al
    Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00124.
    >> Share

  102. COUTTS SB, Yu AYX
    Tenecteplase for acute stroke: the thrombolysis puzzle.
    Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00172.
    >> Share

  103. HILL G, Regan S, Francis R
    Research priorities to improve stroke outcomes.
    Lancet Neurol. 2022;21:312-313.
    >> Share

    March 2022
  104. BONATI LH, Jansen O, de Borst GJ, Brown MM, et al
    Management of atherosclerotic extracranial carotid artery stenosis.
    Lancet Neurol. 2022;21:273-283.
    >> Share

    February 2022
  105. ZHAO J, Yuan F, Song C, Yin R, et al
    Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00010.
    >> Share

  106. DZIEWAS R
    Nutrition in acute stroke management: food for thought.
    Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00078.
    >> Share

  107. GUTIERREZ J, Turan TN, Hoh BL, Chimowitz MI, et al
    Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.
    Lancet Neurol. 2022 Feb 7. pii: S1474-4422(21)00376.
    >> Share

  108. SAMARASEKERA U
    Jeyaraj Pandian: passionate about improving stroke care in India.
    Lancet Neurol. 2022;21:120.
    >> Share

    January 2022
  109. BAILLIEUL S, Dekkers M, Brill AK, Schmidt MH, et al
    Sleep apnoea and ischaemic stroke: current knowledge and future directions.
    Lancet Neurol. 2022;21:78-88.
    >> Share

  110. PUY L, Cordonnier C
    Stroke research in 2021: insights into the reorganisation of stroke care.
    Lancet Neurol. 2022;21:2-3.
    >> Share

    December 2021
  111. FEIGIN VL
    Primary stroke prevention: useful thresholds?
    Lancet Neurol. 2021 Dec 16. pii: S1474-4422(21)00458.
    >> Share

    November 2021
  112. SCHREUDER FHBM, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, et al
    Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
    Lancet Neurol. 2021;20:907-916.
    >> Share

    September 2021
  113. PANDIAN JD, Sebastian IA
    Integrated approach to stroke burden: are we doing enough?
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00287.
    >> Share


  114. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00252.
    >> Share

  115. CASO V, Mosconi MG
    Lessons to be learned in intracerebral haemorrhage research.
    Lancet Neurol. 2021 Sep 2. pii: S1474-4422(21)00296.
    >> Share

  116. HOWARD DPJ, Rothwell PM
    Asymptomatic carotid stenosis and stroke risk - Authors' reply.
    Lancet Neurol. 2021;20:699.
    >> Share

  117. ABBOTT A
    Asymptomatic carotid stenosis and stroke risk.
    Lancet Neurol. 2021;20:698-699.
    >> Share

  118. ROTHWELL PM, Buchan AM
    A new thrombolytic drug for acute ischaemic stroke.
    Lancet Neurol. 2021;20:687-689.
    >> Share

  119. GUSEV EI, Martynov MY, Nikonov AA, Shamalov NA, et al
    Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Lancet Neurol. 2021;20:721-728.
    >> Share

    July 2021
  120. BANDINI F, Vestito L, Filippi L
    Prehospital scales in acute ischaemic stroke management.
    Lancet Neurol. 2021;20:504.
    >> Share

  121. DUVEKOT MHC, Venema E, Kerkhoff H, Dippel DWJ, et al
    Prehospital scales in acute ischaemic stroke management - Authors' reply.
    Lancet Neurol. 2021;20:504-505.
    >> Share

    June 2021
  122. LI L, Poon MTC, Samarasekera NE, Perry LA, et al
    Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.
    Lancet Neurol. 2021;20:437-447.
    >> Share

  123. HAEUSLER KG, Kirchhof P, Kunze C, Tutuncu S, et al
    Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study.
    Lancet Neurol. 2021;20:426-436.
    >> Share

  124. CHENG X, Dong Q
    Towards individualised secondary prevention after intracerebral haemorrhage.
    Lancet Neurol. 2021;20:411-413.
    >> Share

  125. WASSERLAUF J, Volgman AS
    Monitoring for atrial fibrillation after stroke.
    Lancet Neurol. 2021;20:410-411.
    >> Share

    May 2021
  126. SAMARASEKERA U
    Michael Moskowitz: solving the puzzle of migraine.
    Lancet Neurol. 2021 May 17. pii: S1474-4422(21)00141.
    >> Share

  127. JORDAN LC, DeBaun MR, Donahue MJ
    Advances in neuroimaging to improve care in sickle cell disease.
    Lancet Neurol. 2021;20:398-408.
    >> Share

  128. HACHINSKI V, Avan A, Gilliland J, Oveisgharan S, et al
    A new definition of brain health.
    Lancet Neurol. 2021;20:335-336.
    >> Share

    April 2021
  129. WEAVER NA, Kuijf HJ, Aben HP, Abrigo J, et al
    Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00060.
    >> Share

  130. PANTONI L, Salvadori E
    Location of infarcts and post-stroke cognitive impairment.
    Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00107.
    >> Share

  131. BEST JG, Ambler G, Wilson D, Lee KJ, et al
    Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from
    Lancet Neurol. 2021;20:294-303.
    >> Share

  132. GREENBERG SM
    Cerebral microbleeds and prediction of intracranial haemorrhage.
    Lancet Neurol. 2021;20:252-254.
    >> Share

  133. ZIAI WC, Al-Kawaz M
    Blood pressure management after endovascular therapy.
    Lancet Neurol. 2021;20:248-249.
    >> Share

  134. LAUMANN TO, Ortega M, Hoyt CR, Seider NA, et al
    Brain network reorganisation in an adolescent after bilateral perinatal strokes.
    Lancet Neurol. 2021;20:255-256.
    >> Share

    March 2021
  135. SCHMIDT R, Hofer E
    Identifying novel genetic risk loci for lacunar stroke.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00099.
    >> Share

  136. TRAYLOR M, Persyn E, Tomppo L, Klasson S, et al
    Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.
    Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00031.
    >> Share

  137. ENGELTER ST, Traenka C, Gensicke H, Schaedelin SA, et al
    Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.
    Lancet Neurol. 2021 Mar 22. pii: S1474-4422(21)00044.
    >> Share

  138. HOWARD DPJ, Gaziano L, Rothwell PM
    Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.
    Lancet Neurol. 2021;20:193-202.
    >> Share

  139. VAN DIJCK JTJM, Kompanje EJO, Nederkoorn PJ, Peul WC, et al
    Advanced consent for acute stroke trials - Authors' reply.
    Lancet Neurol. 2021;20:170-171.
    >> Share

  140. SHAMY M, Dewar B, Niznick N, Nicholls S, et al
    Advanced consent for acute stroke trials.
    Lancet Neurol. 2021;20:170.
    >> Share

  141. SPENCE JD
    Treatment of asymptomatic carotid stenosis.
    Lancet Neurol. 2021;20:163-165.
    >> Share

    February 2021
  142. MAZIGHI M, Richard S, Lapergue B, Sibon I, et al
    Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2021 Feb 26. pii: S1474-4422(20)30483.
    >> Share

    January 2021
  143. DUVEKOT MHC, Venema E, Rozeman AD, Moudrous W, et al
    Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30439.
    >> Share

  144. GOYAL M, Marko M
    Optimising prehospital stroke triage in a changing landscape.
    Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30488.
    >> Share

  145. TSIVGOULIS G, Katsanos AH
    Important advances in stroke research in 2020.
    Lancet Neurol. 2021;20:2-3.
    >> Share

    December 2020
  146. WU S, Anderson CS
    Healthy eating for secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30450.
    >> Share

  147. ENGLISH C, MacDonald-Wicks L, Patterson A, Attia J, et al
    The role of diet in secondary stroke prevention.
    Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30433.
    >> Share

  148. SILBERGLEIT R, Dickert NW
    Context and principles must drive alternatives to consent in emergency research.
    Lancet Neurol. 2020;19:968-969.
    >> Share

    November 2020
  149. THE LANCET NEUROLOGY
    A unified European action plan on stroke.
    Lancet Neurol. 2020 Nov 6. pii: S1474-4422(20)30409.
    >> Share

    October 2020
  150. MERETOJA A, Yassi N, Wu TY, Churilov L, et al
    Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2020 Oct 28. pii: S1474-4422(20)30369.
    >> Share

  151. KOMPANJE EJO, van Dijck JTJM, Chalos V, van den Berg SA, et al
    Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke.
    Lancet Neurol. 2020 Oct 21. pii: S1474-4422(20)30276.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016